Sanofi
Dupixent
allergic fungal rhinosinusitis
Resolved
85days ago
Approval decision · Apr 13, 2026
What's at stake
A final FDA approval decision on Dupixent for allergic fungal rhinosinusitis is expected Apr 13, 2026.
Primary source
· SEC 6-K
verified 12h ago
“The latest approval expands Dupixent’s indication for CSU in the EU to children as young as two years; Dupixent is now approved for children less than 12 years of age across four chronic diseases driven in part by type 2 inflammation.”